Incyte Corp at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter. I'm one of the biotechnology analysts at Goldman Sachs. And we're pleased to have the team from Incyte here with us today. And with us, we have Hervé Hoppenot, CEO of Incyte Pharmaceuticals.
So Hervé, maybe just a big picture question, actually quite a few of them. But as we head into the second half of this year, you have multiple pivotal readouts and NDA submissions on tap. Could you just go over the programs that you're most excited about? What's really coming in the second half? And what do you see as maybe transformative for the company in terms of new developments?
© -
Okay. No -- I mean the year has been an interesting year in terms of news flow with a number of things happening. Recently, just a few weeks ago, we had the first approval for a JAK inhibitor in GVHD. It's a big milestone because it's a very important disease,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
